BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival

Bristol Myers Squibb is walking away from its $650 million bet on an Eisai antibody-drug conjugate (ADC). The Japanese drugmaker said BMS decided to end the co-development agreement as part of an ongoing portfolio prioritization push.